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Background: Consumers are increasingly turning to plant-based complementary and alternative medicines to treat
hypercholesterolemia. Many of these treatments are untested and their efficacy is unknown. This multitude of
potential remedies necessitates a model system amenable to testing large numbers of organisms that maintains
similarity to humans in both mode of drug administration and overall physiology. Here we develop the larval
zebrafish (4–30 days post fertilization) as a vertebrate model of dietary plant-based treatment of
hypercholesterolemia and test the effects of Crataegus laevigata in this model.
Methods: Larval zebrafish were fed high cholesterol diets infused with fluorescent sterols and phytomedicines.
Plants were ground with mortar and pestle into a fine powder before addition to food. Fluorescent sterols were
utilized to optically quantify relative difference in intravascular cholesterol levels between groups of fish. We utilized
the Zeiss 7-Live Duo high-speed confocal platform in order to both quantify intravascular sterol fluorescence and to
capture video of the heart beat for determination of cardiac output.
Results: In this investigation we developed and utilized a larval zebrafish model to investigate dietary plant-based
intervention of the pathophysiology of hypercholesterolemia. We found BODIPY-cholesterol effectively labels diet-
introduced intravascular cholesterol levels (P < 0.05, Student’s t-test). We also established that zebrafish cardiac
output declines as cholesterol dose increases (difference between 0.1% and 8% (w/w) high cholesterol diet-treated
cardiac output significant at P < 0.05, 1-way ANOVA). Using this model, we found hawthorn leaves and flowers
significantly reduce intravascular cholesterol levels (P < 0.05, 1-way ANOVA) and interact with cholesterol to impact
cardiac output in hypercholesterolemic fish (2-way ANOVA, P < 0.05 for interaction effect).
Conclusions: The results of this study demonstrate that the larval zebrafish has the potential to become a powerful
model to test plant based dietary intervention of hypercholesterolemia. Using this model we have shown that
hawthorn leaves and flowers have the potential to affect cardiac output as well as intravascular cholesterol levels.
Further, our observation that hawthorn leaves and flowers interact with cholesterol to impact cardiac output
indicates that the physiological effects of hawthorn may depend on diet.Background
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the management of blood cholesterol (CH) levels. Des-
pite a poor understanding of the efficacy and effects of
these treatments consumers can find dozens of over-the-
counter plant-based CH remedies at local grocery stores
or pharmacies. Not surprisingly, practitioners of Western
medicine frequently dismiss phytomedical options due to
the lack of experimentally derived data on their effects
and modes of action. One reason for this empirical def-
icit is that each plant has numerous potential effects and
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the effects of these treatments may be subtler than those
of purified Western pharmaceuticals, all of which neces-
sitates testing large numbers of organisms. Mammalian
model systems offer a potential solution to this problem
however, while offering the benefit of a close phylogen-
etic proximity to humans, they are expensive to house
and to maintain. Alternatively, cell culture-based models
of disease offer the advantage of significantly higher-
throughput testing at substantially lower cost. Unfortu-
nately, in vitro experiments can recapitulate neither the
biological complexity nor the physiochemical connectiv-
ity of an intact vertebrate system. As a result, the extent
to which these data represent the patterns and processes
in the actual human disease condition is somewhat
limited.
The high-fecundity, rapid development, low husbandry
costs and optical clarity of their larvae have contributed to
the zebrafish's emergence as a premier vertebrate model in
biomedicine [2]. Several studies have demonstrated that
zebrafish digestive physiology and lipid metabolism are very
similar to that of humans and that treatment of zebrafish
with antihyperlipidemic drugs elicits similar responses to
their mammalian counterparts [3-6]. Recent work has also
shown that zebrafish exhibit similarities to human lipid-
related pathologies including increased vascular permeabil-
ity and thickening, increased levels of total CH, LDL and
oxidized cholesteryl esters [5,7]. Further, blood serum lipid
levels in adult zebrafish can be reduced by treatment with
herbal extracts of laurel, turmeric, cinnamon and clove
[8,9]. These data are promising, and combined with the ob-
servation that the cardiodynamic response of embryonic
zebrafish to many pharmacological agents is similar to those
observed in mammals [10-15] makes it a potentially power-
ful nontraditional model for studying the physiological
effects of a high cholesterol diet (HCD) and its treatment
through diet-based phytomedical interventions.
Western pharmaceutical medicine is largely based on a
reductionist paradigm of both disease and its treatment
where an emphasis is placed upon the molecular
mechanics of single purified/synthesized molecules and
their influence on specific body receptors. A more holis-
tic view of disease and its treatment, where whole plant
products are administered, may allow for treatment of
not only one characteristic of the disease but potentially
several of its peripheral aspects as well [16,17]. In con-
trast to the inherent complexity involved in analyzing
the molecular interactions and specific physiological
effects of each potentially active component in a phy-
totherapy, we propose to initially focus only on holistic-
ally relevant bioprocesses. In this study we measure both
CH and cardiac output (CO) as indicators of overall car-
diovascular health under conditions of diet-induced
hypercholesterolemia. We suggest that the ability of anytreatment (CAM or traditional) to positively alter these
metrics indicates a potent therapeutic potential.
The hawthorn (Crataegus sp.) plant has been utilized
for thousands of years to treat a variety of illnesses. In
Eastern Traditional medical systems, hawthorn is com-
monly used to alleviate digestive ailments and poor cir-
culation. In Western medicine, particularly in Europe,
the hawthorn plant is utilized to treat cardiovascular
maladies such as cardiac failure for which it is certified
to treat New York Heart Association Type II heart fail-
ure [18]. Its purported cardiotonic properties include
inotropic, chronotropic [19] and vasodilatory effects [20],
but the evidence for these effects comes largely from iso-
lated organ and cell culture-based studies where the
overall whole-animal physiological impact cannot readily
be assessed. Hawthorn is also purported to possess anti-
hypercholesterolemic properties. A recent study by Dalli
et al. [21] revealed that leaf and flower extracts of Cra-
taegus laevigata (HLF) appeared to lower LDL CH levels
in diabetic patients with coronary heart disease, although
their results were not statistically significant. Similarly,
studies in both rats and rabbits have demonstrated hypo-
lipidemic effects of hawthorn berries (HB) [22,23]. Po-
tential antihypercholesterolemic effects and cardiotonic
activity suggests hawthorn may have substantial utility as
a treatment for the multi-faceted pathophysiology of
lipid-based diseases.
Here we present data demonstrating the utility of the
zebrafish model in empirically assessing the therapeutic
potential of CAMs by testing whole plant treatments on
animals with diet-induced hypercholesterolemia. This
holistic approach to treatment recognizes that putative
synergistic actions of components of the plant may
have benefits different from those conferred by each in-
dividual molecule [16,17]. We begin by experimentally
identifying the best optical marker for quantifying diet-
induced hypercholesterolemia in the larval zebrafish. We
then use our animal model system to assess the effects
of hawthorn on the cardiovascular pathophysiology of
hypercholesterolemia and finally, we test the ability of a
commonly used CAM, hawthorn, to influence CO in
both healthy and diseased animals.
Methods
Zebrafish care
Adult zebrafish were housed in the Cincinnati Children’s
Hospital Medical Center (CCHMC) - University of Cin-
cinnati (UC) zebrafish facility. Embryos were generated
for this study from in-house lines of adult fish being
bred, raised, and cared for according to established pro-
cedures [24]. Specific ethical approval was given for all
zebrafish husbandry and experimental procedures per-
formed at CCHMC and UC by the Institutional Animal
Care and Use Committee (IACUC) protocol # 1D03020.
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temperature = 26.5-28.5°C; conductivity = 490–530 μS;
and dissolved oxygen concentration = 5.0-7.5 mg L-1
were rigorously maintained through real-time computer-
ized monitoring and dosing. For this study we crossed
transgenic TG(kdrl:mCherry) zebrafish with mCherry
fluorescent protein driven by the cardiovascular specific
kdrl promoter with a casper line containing a melano-
cyte/iridophore mutation [25]. The resulting double
transgenic animals TG(Kdrl:mCherry)/Casper express
red fluorescence in the vascular walls and are optically
transparent through adulthood.Food preparation
An HCD was created by mixing AZOO artificial Artemia
with cholesterol (Invitrogen) in diethyl ether (Sigma). 5–
80 μg/gfood 23-(dipyrrometheneboron difluoride)-24-
norcholesterol (BOD-CH. TopFluor, Avanti Polar Lipids)
and 5–80 μg/gfood 22-(N(−7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino)-23,24-bisnor-5-cholen-3β-ol (NBD-CH. Invi-
trogen) were added to food in both control and HCD after
Stoletov et al., 2009 [4]. Hawthorn (Crataegus laevigata)
leaves and flowers, hawthorn berries, and whole goldenrod
(Solidago virgaurea) were obtained from Starwest Botani-
cals (Rancho Cordova, California). Goldenrod was utilized
as a negative control to assure that plant-infused food itself
did not lead to decreased fluorescent output. Herbal treat-
ments were mixed into food at 6% and 12% (w/w) with
cholesterol and diethyl ether. In the sterol fluorophore-
based experiments, this combination was allowed to dry
after which BOD-CH was added.Measurement of fluorophore levels
From 4–8 days post fertilization (dpf ) zebrafish embryos
were fed paramecia and housed in 1 L breeding tanks
(Aquatic Habitats). Larval fish (8–21 dpf) were trans-
ferred to the main system and fed approximately 2 mg of
food labeled with fluorescent sterol daily. Food weight
for each treatment was measured every other day. Fish
were not given normally scheduled feedings prior to im-
aging. Fish were anesthetized in 125-150 mg L-1 MS-222
(tricaine) and mounted in 1.2% agarose in glass bot-
tomed viewing slides. Confocal imaging was performed
using a LSM 710 platform within the Live Microscopy
Core at the University of Cincinnati. Nine mid-sagittal
Z-plane cross-sections were taken for each fish at a mag-
nification of 20x. BOD-CH and NBD-CH were excited
with a laser at 488 nm, and 458 nm λs respectively and
emission captured between 503-580 nm, and 500-
558 nm λs respectively. Mean fluorescence intensity of
each individual Z-stack was calculated by automated
analysis of collated images from collected mid-sagittal Z-
stacks using Improvision Volocity (Perkin Elmer).Ezetimibe treatment method
Method adapted from a protocol kindly provided by Ste-
ven Farber, PhD. At 4 dpf embryos were incubated in
96-well plates with 100 μL solution per well. Solutions
were made in 1 mL preparations and divided into 10
wells with 2 fish in each well. The ezetimibe treatment
consisted of 2.5% v/v egg yolk in tank water with 50 μM
ezetimibe (Ryan Scientific) (from a stock concentration
of 10 mg/mL in DMSO), and 2.5 μg/mL BOD-CH (8 μL
stock at a concentration of 0.3125 μg/μL in DMSO). The
control solution was exactly the same except without
ezetimibe. After incubation for 4 hours, fish were
extracted from the treatments and allowed to swim in
tank water for 6 hours. Fish were then imaged and data
was analyzed as above.
Percent diet uptake
For each treatment, 5 fish at 19 dpf were placed in a
100 mL beaker filled with 50 mL of tank water. The
treatments were plain food (control), 4%CH-treated food,
and 4%CH+6%HLF-treated food. 10 mg of each diet
was fed to each treatment group (2 mg per fish). After 3
hours feeding, fish were carefully removed from water so
as not to disturb remaining food. Water was poured
through previously weighed Whatman filter paper.
Whatman paper with food was allowed to dry and
weighed again. The final weight of the dry Watman
paper with food was subtracted from the initial weight to
obtain the total weight of food remaining after feeding.
This value was then subtracted from the initial amount
of food fed to each group, which gave the total amount
of food eaten. To determine the percent intake, the total
amount of food eaten was divided by the initial amount
of food administered. This experiment was repeated 3
times.
Cardiac output determination
TG(Kdrl:mCherry)/Casper animals were anesthetized in
tricaine and mounted in agarose as described above.
Feeding and care regimen were also the same except fish
were fed experimental diet until 27 dpf. Fish were
mounted in an upright fashion (aligned vertically) with
the dorsoventral axis in vertical orientation to view the
ventricular chamber from the ventral side of the fish. For
these experiments, an inverted Zeiss 7-Live imaging sys-
tem was utilized to capture high-speed confocal images.
Images were captured at an excitation λ of 560 nm and
emission was gathered with a long-pass 560 nm filter at
23 frames per second for 5 seconds. Cardiac output was
calculated by measuring the equatorial (a) and polar radii
(b) of the ventricular chamber assuming the shape of the
ventricle approximates a prolate spheroid with the equa-
tion: Vventricle = 43 × πa
2b, where Vventricle is the volume of
the ventricle. Vdiastole – Vsystole =ΔV, represents stroke
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cardiac output.
Statistics
Regression analyses, 1-way ANOVAs, 2-way ANOVAs
and student’s t-tests were performed on SigmaStat soft-
ware. Holm-Sidak post-hoc multiple comparison proced-
ure was implemented for all ANOVA tests where
significant differences were observed. In all experiments,
data from fish with morphological defects were not
included in statistical analyses.
Results
BODIPY-cholesterol is a better marker of intravascular
cholesterol accumulation than NBD-cholesterol
To find a reliable optical marker of diet-induced intra-
vascular cholesterol levels, we compared fluorescent
sterol probes BOD-CH and NBD-CH. Our initial experi-
ment tested the ability of each fluorescent sterol to label
intravascular CH levels due to dietary intake. We fed
diets with equal concentrations of fluorophore added to
0% and 4% HCD-fed groups. We also confirmed similar
development of 0% and 4% HCD-fed fish by measuring
body length (see Additional file: 1 Figure S1). Fish in the
4% HCD+BOD-CH treated group showed increased
fluorescence compared to controls while NBD-CH trea-
ted fish demonstrated almost no difference between 4%
and 0% HCD-fed groups (Figure 1A and 1B). To deter-
mine the optimal CH concentration for future
fluorophore-based experiments, we tested the relation-
ship between CH and fluorophore uptake into the vascu-
lature as each were proportionally increased, e.g. 0.5%
CH+5 μg/g fluorophore was fed in the lowest level
treatment group and 8% HCD+ 80 μg/g fluorophore was
fed in the highest dose treatment group. NBD-CH
demonstrated a linear increase in fluorescence with CH
dose, but the rate of increase in fluorescence with dose
of cholesterol was much less than that of BOD-CH
(Figure 1E). BOD-CH treated fish, under the same ex-
perimental conditions, showed a much stronger relation-
ship between BODIPY fluorescence and cholesterol dose
between 0.5-4% HCD. In treatments with an HCD ran-
ging from 4-8% this relationship declined markedly
(Figure 1D) and so we chose 4% HCD+BOD-CH as
optimum to test the effects of HB and HLF on intravas-
cular CH levels.
Dietary administration of hawthorn leaves and flowers
improves intravascular cholesterol levels in zebrafish
model of hypercholesterolemia
In order to test the response of hypercholesterolemic
zebrafish to plant-based dietary intervention, we fed fish
a diet containing phytomedicine and CH. We treated
HCD-fed fish with HB, HLF and GR infused diets dailybetween 8–20 dpf. To each group we added equivalent
amounts of BOD-CH. We found that HLF significantly
decreased intravascular BOD-CH fluorescence levels
compared to HCD-treated controls in our model
(Figure 2.). These results agree with the proposed antihy-
percholesterolemic effects of HLF in humans. To ensure
the decreased fluorescence intensity due to HLF treat-
ment was not due to decreased dietary uptake, we tested
the percent uptake of regular, CH-treated and CH+
HLF-treated diets. The uptake of the diets was nearly
identical between these groups. Further, as a
positive control to ensure BOD-CH fluorescence relates
to CH level, we treated fish with the Neimann-Pick C1
Like-1 (NPC1L1) receptor inhibitor ezetimibe, a potent
blocker of intestinal cholesterol absorption. This lead
to decreased intravascular BOD-CH fluorescence
(Figure 2D and 2E), which implies that BOD-CH uptake
is similar to cholesterol and further validates our model.
A high cholesterol diet decreases cardiac output in the
zebrafish model
The purpose of this experiment was to determine
whether an HCD impairs cardiovascular performance in
the fish, and in doing so elucidate an optimal CH dose
to induce cardiac dysfunction. Cardiac output (CO) is an
excellent measure of overall cardiovascular function, as
its measurement provides information about volume
flow throughout the cardiovascular system as well as car-
diac dynamics. As expected, an increasing dose of CH
correlated with decreased CO (Figure 3A). Significantly
impaired function was observed at 8% HCD compared
to the lowest dose (0.1% HCD) (Figure 3A). This de-
crease appears to have been due to a decreased stroke
volume (SV) as evidenced by a similar relationship be-
tween SV and CO to percent CH in the diet (Figure 3B).
There was no apparent correlation between HR and per-
cent CH (Figure 3C). Taken together, this data indicates
that the zebrafish develops significantly weakened car-
diovascular function after 3 weeks of 8% HCD feeding.
Therefore, our results provide evidence that the larval
zebrafish can be utilized to test the effects of an HCD on
cardiodynamic pathophysiology.
Hawthorn leaves and flowers interact with cholesterol to
affect cardiac output
The ability of HLF to decrease intravascular CH levels
indicates that it is a potential treatment for hypercholes-
terolemia, but its impact on the peripheral pathology of
this disease is unknown. We therefore used our model to
test the ability of HLF to impact HCD-induced
cardiac pathophysiology. Two-way ANOVA analysis
revealed a significant interaction between HLF and CH
in their effects on CO (Figure 4A). CH and HLF do not














A. B. C. 
Figure 1 BODIPY-cholesterol (BOD-CH) vs. NBD-cholesterol (NBD-CH). A. Green is BOD-CH and NBD-CH fluorescence. Arrows point to
fluorescent deposits in vasculature. Top panel: 0% HCD+ 10 μg/g BOD-CH vs. 4% HCD+ 10 μg/g BOD-CH. Bottom panel: 0% HCD+ 10 μg/g NBD-
CH vs. 4% HCD+10 μg/g NBD-CH B. 0% HCD+ 10 μg/g BODIPY-CH shows significantly less fluorescent output than 4% HCD+10 μg/g BOD-CH
(*P < 0.05, Student’s t-test. n = 12 in each group) C. 4% HCD+ 10 μg/g NBD-CH is not different from 0% HCD+ 10 μg/g NBD-CH D. Dose response:
BOD-CH fluorescence vs. percent cholesterol in diet. 0.5-8% HCD+5-80ug/g BOD-CH (R = 0.912, R2 = 0.83). 1-way ANOVA with Holm-Sidak multiple
comparison indicates statistically significant difference between each group and every other group (P < 0.05, n = 11-12 in each group) E. Dose
response: NBD-CH fluorescence vs. percent cholesterol in diet (R = 0.811, R2 = 0.657). Each group is significantly different from all others (P < 0.05, 1-
way ANOVA, Holm-Sidak multiple comparison. n = 10-12 in each group) except 0.5, 1 and 2% which are not significantly different from each other
in any combination.
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between HLF and CH in affecting CO can be explained
by the combined influence of both SV and HR.
Supporting this contention, with this more detailed
analysis, we were able to detect a significant effect of CH
on both SV and HR (Figure 4B and 4C).
Discussion
One goal of this study was to develop the larval zebrafish
as a model to test the efficacy of the numerous potential
phytotherapeutic treatments of hypercholesterolemia. The
other purpose of our work was to exercise a holistic per-
spective to the treatment and quantification of disease that
is relatable to the traditional philosophies prescribing these
medicines.
Our initial experiments focused on finding a fluores-
cent marker for dietary CH intake. This was so
we could later test the ability of selected wholephytomedicines to treat hypercholesterolemia. Utilizing
BOD-CH, we were able to see a significant difference
in intravascular fluorescence between HCD-treated and
control fish that we did not see in the NBD-treated
group. The accumulation of sterol-based fluorophore
deposits in the vasculature of HCD-fed zebrafish was
first observed in [4] with the probe cholesteryl-BOD-
IPY. In our experiments with BOD-CH, we also
observed more fluorescent deposit formation in the
vasculature of HCD-fed, BOD-CH treated fish than in
controls (Figure 1A), however, the formation of these
deposits was extremely variable between individuals. In
the NBD-CH treated group we saw a large amount of
fluorescent deposit accumulation in the vascular endo-
thelium of both control and treated groups
(Figure 1A). These results indicate that an HCD did
not influence the formation of these deposits in NBD-
treated fish (Figure 1A). A potential reason for this is
A. B. 
C. D. E. 
Figure 2 Hawthorn Leaves and Flowers (HLF) Decrease BODIPY-cholesterol fluorescence in 4%HCD-fed fish. A. Representative images of
the vasculature of fish in 4%HCD and 4%HCD+HLF treated fish. Orange vasculature from TG(Kdrl:mCherry)/Casper line. Green is intravascular BOD-
CH fluorescence B. Fluorescence output comparison between groups. Analyzed relative to mean of 4% HCD group having a value of 1. Significant
difference between HLF and 4%HCD treated fish. * P < 0.05, bars are mean± S.D. 1-way ANOVA, Holm-Sidak post-hoc multiple comparison. n = 15-
17 per group. C. Comparison of percent uptake between untreated (control), CH-treated, and CH+HLF-treated diets. Five in each experimental
group, with the experiment repeated 3x, showed similar uptake (P = 0.925, bars are mean± S.D. of repeated experiments. 1-way ANOVA). D.
Representative Images of BOD-CH treated and BOD-CH+ Ezetimibe treated fish (4 dpf). E. Ezetimibe treatment decreases intravascular BOD-CH
fluorescence (* P < 0.05, bars are mean± S.D. 1-way ANOVA, Holm-Sidak post-hoc multiple comparison. n = 13-14 per group).
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oxysterol, 25-hydroxycholesterol, than it does to CH it-
self [26]. Therefore, 22-NBD-cholesterol may not be
physiologically processed similarly to cholesterol. Sup-
porting this argument, Adams et al. [27] demonstrated
that NBD-CH is absorbed by an ezetimibe-insensitive
and Neimann-Pick C1 Like-1 (NPC1L1) protein inde-
pendent pathway. This indicates that the intestinal ab-
sorption of NBD-CH is different from native CH as
ezetimibe acts to block the intestinal absorption of CH
by inhibiting NPC1L1. More work needs to be done to
confirm the metabolism and localization of BODIPY-cholesterol in the zebrafish is similar to native CH, but
our results and the work of others indicate that it is
likely comparable [28,29].
Utilizing our methodology, we found that HLF signifi-
cantly reduced intravascular BOD-CH levels in HCD-fed
fish. There was a slight but not significant decrease in
BODIPY fluorescence in the HB treated group. There-
fore, it is likely that berries are a less potent CH reducing
treatment than HLF. This information may help to iden-
tify a class of compounds in Crataegus laevigata
responsible for decreasing CH levels. HLF and HB
have many potentially active ingredients in common,
Diastole Systole A. 
B. C. 
D. 
Figure 3 Cardiac Output (CO) Decreases with Increasing Cholesterol (CH) Dose. A. Measurement of ventricular diastole and systole in TG
(Kdrl:mCherry)/Casper transgenic to derive stroke volume (SV) in order to finally calculate CO B. CO decreases with increasing CH dose from 0.1-8%
HCD (R = 0.397, R2 = 0.158). Difference between 0.1% and 8%HCD effect on CO is significant C. SV also decreases with increasing CH dose from
0.1-8%HCD (R = 0.396, R2 = 0.157). Difference between 0.1% and 8%HCD effect on SV is significant C. There is not a relationship between HR and
CH dose. * P < 0.05, points are mean± S.D. 1-way ANOVA, Holm-Sidak post-hoc analysis. n = 12-13 per group.
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three treatments tested (HLF, HB and GD) contain flavo-
noids [30,31]. It is therefore unlikely that the flavonoid
components are affecting vascular CH levels. HLF (Cra-
taegus laevigata) contain 1.2-1.6% procyanidin content
whereas HB contains 0.2% procyanidin [30]. There is no
data to our knowledge suggesting that GR contains pro-
cyanidins, this difference in procyanidin content could
account for the reduced ability of HB to impact CH
levels compared to HLF. It also explains why GR failed
to impact intravascular BOD-CH fluorescence.
Our holistic approach yielded a surprising result:
While the combination of CH/HLF slightly improved
CO compared to CH alone, fish treated with either
CH or HLF alone exhibited decreased CO. In essence,
there was no combined effect between CH and HLF to
decrease CO; rather CH and HLF together resulted in
improved CO compared to CH treatment alone. This
result illustrates the benefit of a holistic approach totreatment where there is a strong potential for un-
anticipated effects. In order to explain these results
however, it is necessary to apply a reductionist lens to
our analysis. Long et al. [32] found that some fractions
of Crataegus oxycantha leaves and flowers have a nega-
tive chronotropic effect on isolated cardiomyocytes
while others have a positive chronotropic effect. This
indicates that different components of hawthorn can
have contradictory effects, suggesting that if the bal-
ance between components is altered, the effects of the
treatment can be changed. In our experiment, two-way
ANOVA analysis revealed a significant interaction be-
tween CH and HLF in their effects on CO. We
hypothesize that when zebrafish were fed CH/HLF,
negatively inotropic components of HLF sequestered
CH. More specifically, procyanidin components of HLF
blocked intestinal absorption of CH and therefore
could not affect CO. The balance of positively and
negatively inotropic components was therefore altered
A. B. 
C. 
Figure 4 Hawthorn leaves and flowers (HLF) interact with cholesterol (CH) to impact cardiac output (CO). A. HLF show significant
interaction with CH in their influence on CO. CH decreases CO within 0% HLF and CH decreases CO when comparing all 0% CH-treated to all 8%
CH-treated fish B. No interaction effect was observed on stroke volume (SV). CH decreases SV within 0% HLF and CH decreases SV when
comparing all 0% CH-treated to all 8% CH-treated fish C. No interaction effect was observed on heart rate (HR). CH decreases HR when comparing
all 0% CH-treated to all 8% CH-treated fish. * P < 0.05, bars are mean+ S.D. 2-way ANOVA with Holm-Sidak post-hoc analysis. n = 12-19 per group.
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components. Combined with a reduction in cholesterol
levels, this increase of available positive inotropic plant
constituents lead to the CO increase in CH/HLF trea-
ted fish compared to CH-treated.
This array of potential effects and treatment paradigms
from which to view a single phytomedicine demonstrates
the need for experimenting with a large number of organ-
isms. It would therefore be beneficial to have a high
throughput method capable of assessing the ability of these
phytomedicines to treat HCD-induced cardiovascular dis-
ease. The zebrafish model organism provides an excellent
opportunity to achieve this, as zebrafish-based high-
throughput screening methods capable of screening for
cardiovascular disease are a burgeoning method of drug
discovery. With high-throughput screening, it will be pos-
sible to test compound classes to derive the synergistic
effects of the plant parts and which ratio of, for example,
procyanidin to flavonoid, best treats a particular disease.Conclusions
The results of this study demonstrate that HLF are a
promising treatment for hypercholesterolemia. We have
created a vertebrate model system to test plant-based
dietary intervention of hypercholesterolemia using the
zebrafish. We utilized this model to demonstrate that
HLF decrease intravascular CH levels and interact with
cholesterol to improve CO in diseased fish. These results
indicate that the cardiotonic action of hawthorn may de-
pend on diet. Further work is needed to understand the
detailed mechanism of how HLF exerts its influence.
While hawthorn is not currently a recommended treat-
ment for hypercholesterolemia, our research indicates it
may be an effective treatment for this disease.
Additional file
Additiopnal file 1: Figure S1. Zebrafish Length Assessment: 0% vs.
4% High Cholesterol Diet (HCD). Comparison of zebrafish length
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